ENPICOMAdopting AI in biologics discovery
The global biologics market was estimated at $400B in 2024 and is projected to exceed $650B by 2030, potentially outpacing small molecules. Yet, the path to that growth is constrained by the inherent complexities of biologics discovery: noisy data, costly wet-lab cycles, and long timelines. As a result, AI is quickly shifting from a "nice-to-have" novelty to a critical decision-guiding capability in biologics discovery, helping teams move faster, reduce risk, and focus experimentation where it has the highest impact.
Produced in partnership with Labiotech, this report breaks down how leading organizations are approaching AI adoption: what’s working, what’s not, and what capabilities need to be in place to turn AI into measurable impact.
Key insights + takeaways:
- The promise of AI in biologics discovery and development
- The most common real-world adoption blockers and what it takes to overcome them: robust data infrastructure, advanced compute, and multidisciplinary talent
- How teams can reduce reliance on massive standardized datasets by augmenting experimental data
- Executive perspectives and lessons learned from leaders across the industry, including Boehringer Ingelheim, Daiichi Sankyo Europe, OncoHost, and more
